Cytokine networks in the infected lung

Expert Review of Respiratory Medicine

Volumn 2, Issue 6, 2008, Pages 739-752

  Bhan, Urvashi ^a   Cornicelli, Matthew D ^a   Standiford, Theodore J ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Acquired immunity; Chemokine; Cytokine; Host defense; Immunotherapy; Innate immunity; Pneumonia

Indexed keywords

ALPHA CHEMOKINE; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN G; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; BACTERIAL PNEUMONIA; CELL ACTIVATION; CELL SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; EPITHELIUM CELL; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LEUKOCYTE ACTIVATION; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; TH1 CELL;

EID: 65449172863     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2.6.739     Document Type: Review

References (119)

1. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2), 179-186 (2003).
2. Koth LL, Alex B, Hawgood S et al. Integrin β6 mediates phospholipid and collectin homeostasis by activation of latent TGF-β1. Am. J. Respir. Cell. Mol. Biol. 37(6), 651-659 (2007).
3. Landsman L, Jung S. Lung macrophages serve as obligatory intermediate between blood monocytes and alveolar macrophages. J. Immunol. 179(6), 3488-3494 (2007).
4. Taut K, Winter C, Briles DE et al. Macrophage turnover kinetics in the lungs of mice infected with Streptococcus pneumoniae. Am. J. Respir. Cell. Mol. Biol. 38(1), 105-113 (2008).
5. Hajjar AM, Harowicz H, Liggitt HD, Fink PJ, Wilson CB, Skerrett SJ. An essential role for non-bone marrow-derived cells in control of Pseudomonas aeruginosa pneumonia. Am. J. Respir. Cell. Mol. Biol. 33(5), 470-475 (2005).
6. Moore TA, Moore BB, Newstead MW, Standiford TJ. γδ-T cells are critical for survival and early proinflammatory cytokine gene expression during murine Klebsiella pneumonia. J. Immunol. 165(5), 2643-2650 (2000).
7. Chan CW, Crafton E, Fan HN et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12(2), 207-213 (2006).
8. Hoek KL, Cassell GH, Duffy LB, Atkinson TP. Mycoplasma pneumoniaeinduced activation and cytokine production in rodent mast cells. J. Allergy Clin. Immunol. 109(3), 470-476 (2002).
9. Suzuki T, Chow CW, Downey GP. Role of innate immune cells and their products in lung immunopathology. Int. J. Biochem. Cell Biol. 40(6-7), 1348-1361 (2008).
10. Bhan U, Lukacs NW, Osterholzer JJ et al. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J. Immunol. 179(6), 3937-3946 (2007).
11. Osterholzer JJ, Curtis JL, Polak T et al. CCR2 mediates conventional dendritic cell recruitment and the formation of bronchovascular mononuclear cell infiltrates in the lungs of mice infected with Cryptococcus neoformans. Immunol. 181(1), 610-620 (2008).
12. Osterholzer JJ, Ames T, Polak T et al. CCR2 and CCR6, but not endothelial selectins, mediate the accumulation of immature dendritic cells within the lungs of mice in response to particulate antigen. J. Immunol. 175(2), 874-883 (2005).
13. Tovey MG, Lallemand C, Thyphronitis G. Adjuvant activity of type I interferons. Biol. Chem DOI: 10.1515/BC.2008.051 (2008) Epub ahead of print).
14. + T cells mediate antibacterial immunity via CCL3 activation of TNF/ROI phagocytes. J. Exp. Med. 204(9), 2075-2087 (2007).
15. Darwich L, Coma G, Pena R et al. Secretion of interferon-γ by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology DOI: 10.1111/j.1365-2567.2008.02905.x 2008) (Epub ahead of print).
16. Deng JC, Zeng X, Newstead M et al. STAT4 is a critical mediator of early innate immune responses against pulmonary Klebsiella infection. J. Immunol. 173(6), 4075-4083 (2004).
17. Rivera A, Chen CC, Ron N, Dougherty JP, Ron Y. Role of B cells as antigenpresenting cells in vivo revisited: antigenspecific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13(12), 1583-1593 (2001).
18. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85(2), 85-95 2003).
19. Franchi L, Park JH, Shaw MH et al. Intracellular NOD-like receptors in innate immunity, infection and disease. Cell. Microbiol. 10(1), 1-8 (2008).
20. Takeda K, Akira S. Toll-like receptors. In: Current Protocols In Immunology. Chapter 14, Unit 14.12 (2007).
21. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 406(6797), 782-787 2000).
22. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85(2), 85-95 2003).
23. Henning LN, Azad AK, Parsa KV, Crowther JE, Tridandapani S, Schlesinger LS. Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. J. Immunol. 180(12), 7847-7858 (2008).
24. Park JS, Svetkauskaite D, He Q et al. Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279(9), 7370-7377 (2004).
25. Hedl M, Li J, Cho JH, Abraham C. Chronic stimulation of NOD2 mediates tolerance to bacterial products. Proc. Natl Acad. Sci. USA 104(49), 19440-19445 2007).
26. Rosenstiel P, Jacobs G, Till A, Schreiber S. NOD-like receptors: ancient sentinels of the innate immune system. Cell. Mol. Life Sci. 19, 19 (2008).
27. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 14(21), 1929-1934 (2004).
28. Kishore U, Greenhough TJ, Waters P et al. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol. Immunol. 43(9), 1293-1315 (2006).
29. Steele C, Marrero L, Swain S et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 β-glucan receptor. J. Exp. Med. 198(11), 1677-1688 (2003).
30. Steele C, Rapaka RR, Metz A et al. The β-glucan receptor Dectin-1 recognizes specific morphologies of Aspergillus fumigatus. PLoS Pathog. 1(4), E42 (2005).
31. Mehrad B, Standiford TJ. Role of cytokines in pulmonary antimicrobial host defense. Immunol. Res. 20(1), 15-27 (1999).
32. Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J. Biol. Chem. 266(15), 9912-9918 (1991).
33. Standiford TJ, Kunkel SL, Basha MA et al. Interleukin-8 gene expression by a pulmonary epithelial cell line. A model for cytokine networks in the lung. J. Clin. Invest. 86(6), 1945-1953 (1990).
34. Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-γ independent manner. Tuberculosis (Edinb.) 82(2-3), 55-61 (2002).
35. Benini J, Ehlers EM, Ehlers S. Different types of pulmonary granuloma necrosis in immunocompetent vs. TNFRp55-genedeficient mice aerogenically infected with highly virulent Mycobacterium avium. J. Pathol. 189(1), 127-137 (1999).
36. Deepe GS Jr, Gibbons RS. T cells require tumor necrosis factor-a to provide protective immunity in mice infected with Histoplasma capsulatum. J. Infect. Dis. 193(2), 322-330 (2006).
37. Kwon YS, Kim EJ, Lee SH et al. Decreased cytokine production in patients with nontuberculous mycobacterial lung disease. Lung 185(6), 337-341 (2007).
38. Netea MG, Brouwer AE, Hoogendoorn EH et al. Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon-γ therapy. Clin. Infect. Dis. 39(9), E83-E87 (2004).
39. Mancini G, Erario L, Gianfreda R et al. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving antitumour necrosis factor-(anti-TNF-α) treatment. Clin. Microbiol. Infect. 13(10), 1036-1037 (2007).
40. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor a blockade therapy. Mayo Clin. Proc. 83(2), 181-194 (2008).
41. Imaizumi K, Sugishita M, Usui M, Kawabe T, Hashimoto N, Hasegawa Y. Pulmonary infectious complications associated with anti-TNFα therapy (infliximab) for rheumatoid arthritis. Intern. Med. 45(10), 685-688 (2006).
42. Salvana EM, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J. Infect. 55(6), 484-487 (2007).
43. Kafka D, Ling E, Feldman G et al. Contribution of IL-1 to resistance to Streptococcus pneumoniae infection. Int. Immunol. 20(9), 1139-1146 (2008).
44. Fremond CM, Togbe D, Doz E et al. IL-1 receptor-mediated signal is an essential component of MyD88-dependent innate response to Mycobacterium tuberculosis infection. J. Immunol. 179(2), 1178-1189 (2007).
45. Kolsuz M, Erginel S, Alatas O et al. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration 70(6), 615-622 (2003).
46. Akarsu S, Kurt AN, Dogan Y, Yilmaz E, Godekmerdan A, Aygun AD. The differential diagnostic values of cytokine levels in pleural effusions. Mediators Inflamm. 2005(1), 2-8 (2005).
47. Quinton LJ, Jones MR, Robson BE, Simms BT, Whitsett JA, Mizgerd JP. Alveolar epithelial STAT3, IL-6 family cytokines, and host defense during Escherichia coli pneumonia. Am. J. Respir. Cell. Mol. Biol. 38(6), 699-706 (2008).
48. Quinton LJ, Jones MR, Simms BT et al. Functions and regulation of NF-κB RelA during pneumococcal pneumonia. J. Immunol. 178(3), 1896-1903 (2007).
49. Cooper AM, Solache A, Khader SA. Interleukin-12 and tuberculosis: an old story revisited. Curr. Opin. Immunol. 19(4), 441-447 (2007).
50. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19(5), 641-644 (2003).
51. Tateda K, Moore TA, Deng JC et al. Early recruitment of neutrophils determines subsequent T1/T2 host responses in a murine model of Legionella pneumophila pneumonia. J. Immunol. 166(5), 3355-3361 (2001).
52. Walter MJ, Kajiwara N, Karanja P, Castro M, Holtzman MJ. Interleukin 12 p40 production by barrier epithelial cells during airway inflammation. J. Exp. Med. 193(3), 339-351 (2001).
53. Magram J, Connaughton SE, Warrier RR et al. IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses. Immunity 4(5), 471-481 (1996).
54. Cooper AM, Magram J, Ferrante J, Orme IM. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with Mycobacterium tuberculosis. J. Exp. Med. 186(1), 39-45 (1997).
55. Newton CA, Perkins I, Widen RH, Friedman H, Klein TW. Role of Toll-like receptor 9 in Legionella pneumophila-induced interleukin-12 p40 production in bone marrow-derived dendritic cells and macrophages from permissive and nonpermissive mice. Infect. Immun. 75(1), 146-151 (2007).
56. Ruan S, McKinley L, Zheng M et al. Interleukin-12 and host defense against murine Pneumocystis pneumonia. Infect. Immun. 76(5), 2130-2137 (2008).
57. Huang J, Wang MD, Lenz S, Gao D, Kaltenboeck B. IL-12 administered during Chlamydia psittaci lung infection in mice confers immediate and long-term protection and reduces macrophage inflammatory protein-2 level and neutrophil infiltration in lung tissue. J. Immunol. 162(4), 2217-2226 (1999).
58. Happel KI, Dubin PJ, Zheng M et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202(6), 761-769 (2005).
59. Greenberger MJ, Kunkel SL, Strieter RM et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J. Immunol. 157(7), 3006-3012 (1996).
60. Ivanov S, Bozinovski S, Bossios A et al. Functional relevance of the IL-23-IL-17 axis in lungs in vivo. Am. J. Respir. Cell. Mol. Biol. 36(4), 442-451 (2007).
61. Joyee AG, Qiu H, Fan Y, Wang S, Yang X. Natural killer T cells are critical for dendritic cells to induce immunity in Chlamydial pneumonia. Am. J. Respir. Crit. Care Med. 178(7), 745-756 (2008).
62. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928 2004).
63. Zeng X, Moore TA, Newstead MW, Deng JC, Lukacs NW, Standiford TJ. IP-10 mediates selective mononuclear cell accumulation and activation in response to intrapulmonary transgenic expression and during adenovirus-induced pulmonary inflammation. J. Interferon Cytokine Res. 25(2), 103-112 (2005).
64. Strassburg A, Droemann D, van Zandbergen G, Kothe H, Dalhoff K. Enhanced PMN response in chronic bronchitis and community-acquired pneumonia. Eur. Respir. J. 24(5), 772-778 2004).
65. Tsai WC, Strieter RM, Mehrad B, Newstead MW, Zeng X, Standiford TJ. CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia. Infect. Immun. 68(7), 4289-4296 (2000).
66. Winter C, Taut K, Srivastava M et al. Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J. Immunol. 178(9), 5828-5838 2007).
67. Mehrad B, Wiekowski M, Morrison BE et al. Transient lung-specific expression of the chemokine KC improves outcome in invasive aspergillosis. Am. J. Respir. Crit. Care Med. 166(9), 1263-1268 (2002).
68. Abul H, Abul A, Khan I, Mathew TC, Ayed A, Al-Athary E. Levels of IL-8 and myeloperoxidase in the lungs of pneumonia patients. Mol. Cell. Biochem. 217(1-2), 107-112 (2001).
69. Lindell DM, Standiford TJ, Mancuso P, Leshen ZJ, Huffnagle GB. Macrophage inflammatory protein 1a/CCL3 is required for clearance of an acute Klebsiella pneumoniae pulmonary infection. Infect. Immun. 69(10), 6364-6369 (2001).
70. Stumbles PA, Strickland DH, Pimm CL et al. Regulation of dendritic cell recruitment into resting and inflamed airway epithelium: use of alternative chemokine receptors as a function of inducing stimulus. J. Immunol. 167(1), 228-234 (2001).
71. Phadke AP, Akangire G, Park SJ, Lira SA, Mehrad B. The role of CC chemokine receptor 6 in host defense in a model of invasive pulmonary aspergillosis. Am. J. Respir. Crit. Care Med. 175(11), 1165-1172 2007).
72. Schutte BC, McCray PB Jr. β-defensins in lung host defense. Annu. Rev. Physiol. 64, 709-748 (2002).
73. Hintzen G, Ohl L, del Rio ML et al. Induction of tolerance to innocuous inhaled antigen relies on a CCR7-dependent dendritic cell-mediated antigen transport to the bronchial lymph node. J. Immunol. 177(10), 7346-7354 (2006).
74. Lloyd CM, Delaney T, Nguyen T et al. CC chemokine receptor (CCR)3/ eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191(2), 265-274 (2000).
75. Kikuchi T, Andarini S, Xin H et al. Involvement of fractalkine/ CX3CL1 expression by dendritic cells in the enhancement of host immunity against Legionella pneumophila. Infect. Immun. 73(9), 5350-5357 (2005).
76. Kahnert A, Seiler P, Stein M et al. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur. J. Immunol. 36(3), 631-647 (2006).
77. Arora S, Hernandez Y, Erb -Downward JR, McDonald RA, Toews GB, Huffnagle GB. Role of IFN-γ in regulating T2 immunity and the development of alternatively activated macrophages during allergic bronchopulmonary mycosis. J. Immunol. 174(10), 6346-6356 2005).
78. Bhan U, Trujillo G, Lyn-Kew K et al. Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect. Immun. 76(7), 2895-2904 (2008).
79. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23-35 (2003).
80. Netea MG, Lewis EC, Azam T et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc. Natl Acad. Sci. USA 105(9), 3515-3520 (2008).
81. Lei D, Lancaster JR Jr, Joshi MS et al. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-γ gene. Am. J. Physiol. 272(5 Pt 1), L852-L859 (1997).
82. Woolard MD, Hudig D, Tabor L, Ivey JA, Simecka JW. NK cells in γ-interferondeficient mice suppress lung innate immunity against Mycoplasma spp. Infect. Immun. 73(10), 6742-6751 (2005).
83. Shao C, Qu J, He L et al. Transient overexpression of γ interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin. Exp. Immunol. 142(2), 233-241 (2005).
84. Deng JC, Tateda K, Zeng X, Standiford TJ. Transient transgenic expression of γ interferon promotes Legionella pneumophila clearance in immunocompetent hosts. Infect. Immun. 69(10), 6382-6390 (2001).
85. Kolls JK, Lei D, Stoltz D et al. Adenoviralmediated interferon-γ gene therapy augments pulmonary host defense of ethanol-treated rats. Alcohol Clin. Exp. Res. 22(1), 157-162 (1998).
86. Docke WD, Randow F, Syrbe U et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3(6), 678-681 (1997).
87. Mancuso G, Midiri A, Biondo C et al. Type I IFN signaling is crucial for host resistance against different species of pathogenic bacteria. J. Immunol. 178(5), 3126-3133 (2007).
88. Chen GH, McDonald RA, Wells JC, Huffnagle GB, Lukacs NW, Toews GB. The γ interferon receptor is required for the protective pulmonary inflammatory response to Cryptococcus neoformans. Infect. Immun. 73(3), 1788-1796 (2005).
89. Biondo C, Midiri A, Gambuzza M et al. IFN-α/β signaling is required for polarization of cytokine responses toward a protective type 1 pattern during experimental cryptococcosis. J. Immunol. 181(1), 566-573 (2008).
90. Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/ β. Immunol. Cell Biol. 82(6), 596-602 (2004).
91. Ank N, Iversen MB, Bartholdy C et al. An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J. Immunol. 180(4), 2474-2485 (2008).
92. Gregory AD, Hogue LA, Ferkol TW, Link DC. Regulation of systemic and local neutrophil responses by G-CSF during pulmonary Pseudomonas aeruginosa infection. Blood 109(8), 3235-3243 (2007).
93. Nelson S, Belknap SM, Carlson RW et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with communityacquired pneumonia. CAP Study Group. J. Infect. Dis. 178(4), 1075-1080 (1998).
94. Cheng AC, Stephens DP, Currie BJ. Granulocyte-colony stimulating factor (G-CSF) as an adjunct to antibiotics in the treatment of pneumonia in adults. Cochrane Database Syst. Rev. 2, CD004400 (2007).
95. Berclaz PY, Shibata Y, Whitsett JA, Trapnell BC. GM-CSF, via PU.1, regulates alveolar macrophage Fcγ R-mediated phagocytosis and the IL-18/IFN-γ-mediated molecular connection between innate and adaptive immunity in the lung. Blood 100(12), 4193-4200 (2002).
96. Chen GH, Olszewski MA, McDonald RA et al. Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am J. Pathol. 170(3), 1028-1040 (2007).
97. Gonzalez-Juarrero M, Hattle JM, Izzo A et al. Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J. Leukoc. Biol. 77(6), 914-922 (2005).
98. Nierhaus A, Montag B, Timmler N et al. Reversal of immunoparalysis by recombinant human granulocyte- macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med. 29(4), 646-651 (2003).
99. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized Phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166(2), 138-143 2002).
100. Baleeiro CE, Christensen PJ, Morris SB, Mendez MP, Wilcoxen SE, Paine R 3rd. GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 291(6), L1246-L1255 2006).
101. Moore BB, Coffey MJ, Christensen P et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandindependent mechanism. J. Immunol. 165(7), 4032-4039 (2000).
102. Stockinger B, Veldhoen M, Martin B. Th17 cells: linking innate and adaptive immunity. Semin. Immunol. 19(6), 353-361 (2007).
103. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28(4), 454-467 (2008).
104. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 43(3), 402-407 2008).
105. Umemura M, Yahagi A, Hamada S et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 178(6), 3786-3796 (2007).
106. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Exp. Med. 194(4), 519-527 2001).
107. Rudner XL, Happel KI, Young EA, Shellito JE. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75(6), 3055-3061 (2007).
108. Aujla SJ, Chan YR, Zheng M et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14(3), 275-281 (2008).
109. Milner JD, Brenchley JM, Laurence A et al. Impaired T(h)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452(7188), 773-776 (2008).
110. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(h)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445(7128), 648-651 (2007).
111. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J. Immunol. 159(6), 2858-2866 (1997).
112. Askenasy N, Kaminitz A, Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun. Rev. 7(5), 370-375 (2008).
113. Didierlaurent A, Goulding J, Hussell T. The impact of successive infections on the lung microenvironment. Immunology 122(4), 457-465 (2007).
114. Holscher C, Holscher A, Ruckerl D et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174(6), 3534-3544 (2005).
115. Marriott HM, Hellewell PG, Cross SS, Ince PG, Whyte MK, Dockrell DH. Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J. Immunol. 177(9), 6480-6488 (2006).
116. Janssen WJ, McPhillips KA, Dickinson MG et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRPα. Am. J. Respir. Crit. Care Med. 178(2), 158-167 (2008).
117. Tejera A, Santolaria F, Diez ML et al. Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 TREM-1) and other mediators of the inflammatory response. Cytokine 38(3), 117-123 (2007).
118. Gibot S. TREM, new receptors mediating innate immunity. Med. Sci. (Paris) 20(5), 503-505 (2004).
119. Pai M, Menzies D. Interferon-γ release assays: what is their role in the diagnosis of active tuberculosis? Clin. Infect. Dis. 44(1), 74-77 (2007).